Journal
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
Volume 12, Issue 3, Pages -Publisher
Becaris Publishing
DOI: 10.57264/cer-2022-0049
Keywords
atrial fibrillation; bleeding; coronary artery disease; EMIR; MACE; myocardial infarction; peripheral artery disease; rivaroxaban; stroke; vascular disease
Categories
Ask authors/readers for more resources
This study analyzed the impact of cardiovascular disease on the prognosis of atrial fibrillation (AF) patients and found that patients with cardiovascular disease have a higher risk of adverse cardiovascular events and cardiovascular death.
Aim: It is not well known how comorbidities may change the prognosis of atrial fibrillation (AF) patients. This study was aimed to analyze the impact of cardiovascular disease on this population. Materials & methods: EMIR was a multicenter, prospective study, including 1433 AF patients taking rivaroxaban for >= 6 months. Data were analyzed according to the presence of vascular disease. Results: Coronary artery disease was detected in 16.4%, peripheral artery disease/aortic plaque in 6.7%, vascular disease in 28.3%. Patients with coronary artery disease had higher rates (per 100 patient-years) of major adverse cardiovascular events (2.98 vs 0.71; p < 0.001) and cardiovascular death (1.79 vs 0.41; p = 0.004). Those with vascular disease had higher rates of thromboembolic events (1.47 vs 0.44; p = 0.007), major adverse cardiovascular events (2.03 vs 0.70; p = 0.004), and cardiovascular death (1.24 vs 0.39; p = 0.025). Patients with peripheral artery disease/aortic plaque had similar rates. Conclusion: AF patients with vascular disease have a higher risk of non-embolic outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available